<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0012115'>Hepatitis</z:hpo> B reactivation is a well-known complication during or after chemotherapy in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B (HBV) carriers </plain></SENT>
<SENT sid="1" pm="."><plain>The current practice guidelines in Canada and the United States recommends patients receive antiviral prophylaxis prior to the <z:hpo ids='HP_0003674'>onset</z:hpo> of chemotherapy in <z:hpo ids='HP_0011010'>chronic</z:hpo> HBV carriers with lamivudine </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case of a 57-year-old man with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> on lamivudine prophylaxis and no clinical evidence of <z:hpo ids='HP_0001394'>cirrhosis</z:hpo>, and developed fatal HBV reactivation after the emergence of a YMDD mutant strain of HBV that confers lamivudine resistance </plain></SENT>
<SENT sid="3" pm="."><plain>Fatal reactivation secondary to the development of lamivudine resistance has not, to date, been well- reported </plain></SENT>
<SENT sid="4" pm="."><plain>Our experience indicates the need to carefully monitor patients for suspected drug- resistant HBV mutants with the addition of anti-<z:mp ids='MP_0001799'>viral</z:mp> agents effective against the YMDD mutational strain, when lamivudine resistance emerges </plain></SENT>
</text></document>